A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Sulbactam/Ampicillin in Pneumonia, Aspiration and Lung Abscess, sponsored by Bayer. Completed at 15 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-11.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.
73 studies on the registry are indexed under Pneumonia, Aspiration; 12 are open to participants now.
This study's enrollment of 139 is above the median of 113 across 38 interventional studies indexed under Pneumonia, Aspiration.
Browse Pneumonia, Aspiration studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avelox (Moxifloxacin, BAY12-8039)
Drug: Sulbactam/Ampicillin
Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Drug pages: Sulbactam · Ampicillin
Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events
Time frame: Up to 30 days after end of treatment with study medication for serious adverse events
Clinical Response
Time frame: Regulary doing i.v. treatment
The record gives a start of Feb 2001 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin